BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Durata Therapeutics, Inc. 

89 Headquarters Plaza North
Suite 306
Morristown  New Jersey  07960  U.S.A.
Phone: 646-871-6480 Fax: 973-993-4865


SEARCH JOBS


Industry
Biotechnology






 Company News
FDA Panel Backs Durata Therapeutics, Inc.  (DRTX)'s Two New Anti-Infective Drugs 4/1/2014 7:38:23 AM    More...
Durata Therapeutics, Inc.  (DRTX) Reports Fourth Quarter And Full-Year 2013 Financial Results 3/14/2014 9:14:30 AM    More...
Durata Therapeutics, Inc.  (DRTX) to Announce Full Year 2013 Financial Results on March 14, 2014 3/7/2014 8:39:04 AM    More...
Durata Therapeutics, Inc.  (DRTX) To Present At Upcoming Investor Conferences 3/3/2014 9:01:09 AM    More...
Durata Therapeutics, Inc.  (DRTX) To Present At The RBC Capital Markets' Global Healthcare Conference 2/18/2014 9:07:24 AM    More...
European Medicines Agency Accepts Marketing Authorization Application For Durata Therapeutics, Inc.  (DRTX)'s Dalbavancin 12/23/2013 9:10:22 AM    More...
Durata Therapeutics, Inc.  (DRTX) Submits Marketing Authorization Application For Dalbavancin 12/3/2013 9:10:17 AM    More...
Durata Therapeutics, Inc.  (DRTX) Announces FDA's Acceptance For Priority Review Of NDA For Dalvance™ (Dalbavancin Hydrochloride) 11/27/2013 9:26:00 AM    More...
Durata Therapeutics, Inc.  (DRTX) to Present at the Jefferies 2013 Global Healthcare Conference 11/18/2013 9:18:18 AM    More...
Durata Therapeutics, Inc.  (DRTX) Reports Third Quarter 2013 Financial Results 11/6/2013 9:22:47 AM    More...
1234567

//-->